Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study

Table 2 Grade 3/4 adverse events and adherence/feasibility of each treatment group (n = 63), n (%)

	Conventional (n = 42)	Early (n = 21)	P value
RDI (%), mean ± SD	68.58 ± 27.64	65.34 ± 28.07	0.587
Median (IQR)	73.4 (51.88, 96.25)	67.50 (46.38, 95)
Completion rate
4 cycles	34 (81.0)	17 (81.0)	1.000
8 cycles	16 (38.1)	7 (33.3)	0.786
Dose down rate			0.026
None	31 (73.8)	9 (42.9)
Reduction	11 (26.2)	12 (57.1)
Schedule change rates			0.08
None	26 (61.9)	18 (85.7)
Change	16 (38.1)	3 (14.3)
Adverse event
Overall toxicity	18 (42.9)	12 (57.1)	0.285
Related death	0	0	NA
Leukopenia	4 (9.5)	1 (4.8)	0.657
Neutropenia	15 (35.7)	10 (47.6)	0.363
Thrombocytopenia	8 (19.0)	3 (14.0)	0.639
Anorexia	12 (28.6)	9 (42.9)	0.257
Vomiting	10 (24.4)	4 (19.0)	0.085
Neurotoxicity	1 (2.4)	2 (9.5)	0.219
Diarrhea	3 (7.1)	2 (9.5)	0.742

RDI: Relative dose intensity; IQR: Interquartile range; NA: Not available.